# A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Source: https://onco.cc/trials/nct07347951/  
OnCo record `nct07347951` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by First Affiliated Hospital of Wenzhou Medical University, now recruiting.

## Summary

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer is a phase 2, interventional study registered as NCT07347951 by First Affiliated Hospital of Wenzhou Medical University, with a registry enrolment figure of 30 participants, started 2025-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Short-course radiotherapy; CAPOX chemotherapy; Targeted therapy with bevacizumab; Serplulimab immunotherapy. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "* Diagnosed via pelvic MRI and rectoscopy with a tumor located ≤10 cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes confined within the mesorectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07347951
- Phase: 2
- Setting: A Single-Center, Prospective, Phase II Clinical Study to Evaluate the Preliminary Efficacy and Safety of Short-Course Radiotherapy Followed by CAPOX Chemotherapy Combined With Serplulimab and Bevacizumab as Total Neoadjuvant Therapy for MSS-Type, Mid-Low Locally Advanced Rectal Cancer
- Sponsor: First Affiliated Hospital of Wenzhou Medical University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07347951: https://clinicaltrials.gov/study/NCT07347951

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07347951.json